Literature DB >> 11180122

Induction of neonatal lupus in pups of mice immunized with synthetic peptides derived from amino acid sequences of the serotoninergic 5-HT4 receptor.

P Eftekhari1, J C Roegel, F Lezoualc'h, R Fischmeister, J L Imbs, J Hoebeke.   

Abstract

We have previously suggested that the recognition of a cross-reactive epitope on the 5-HT4 receptor and the 52-kDa SSA/Ro protein by serotonin-antagonizing autoantibodies could explain the electrophysiological symptoms of congenital heart block in neonatal lupus. To confirm this hypothesis, we immunized female mice with four synthetic peptides corresponding to the recognized epitopes. All mice developed anti-peptide antibodies, which cross-reacted with the Ro52 and 5-HT4 receptor peptides and recognized both cognate proteins. Peptide-immune mice were mated. The pups from mice immunized with the Ro52 peptides had no symptoms of neonatal lupus apart from bradycardia. However, pups from mice immunized with the 5-HT4 receptor peptides and bradycardia, atrioventricular block of type I or II, longer QT intervals, skin rashes and neuromotor problems. The 5-HT4 receptor was detectable in the different fetal tissues affected (heart, skin and brain) by immunohistochemistry. Hearts from diseased pups were less developed and showed disorganized myocardial hyperplasia, compared to the normal littermates. These results demonstrate that the serotoninergic 5-HT4 receptor is the antigenic target of physiopathological autoantibodies in neonatal lupus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11180122     DOI: 10.1002/1521-4141(200102)31:2<573::aid-immu573>3.0.co;2-9

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  Losing your nerves? Maybe it's the antibodies.

Authors:  Betty Diamond; Patricio T Huerta; Paola Mina-Osorio; Czeslawa Kowal; Bruce T Volpe
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

2.  SS-56, a novel cellular target of autoantibody responses in Sjögren syndrome and systemic lupus erythematosus.

Authors:  O Billaut-Mulot; C Cocude; V Kolesnitchenko; M J Truong; E K Chan; E Hachula; X de la Tribonnière; A Capron; G M Bahr
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 3.  Role of calcium channels in congenital heart block.

Authors:  E Karnabi; M Boutjdir
Journal:  Scand J Immunol       Date:  2010-09       Impact factor: 3.487

Review 4.  Maternal antibodies and developing blood-brain barrier.

Authors:  Czeslawa Kowal; Andrew Athanassiou; Huiyi Chen; Betty Diamond
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

Review 5.  Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus.

Authors:  Deborah M Friedman; Ann Rupel; Jill P Buyon
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

Review 6.  Neonatal lupus: clinical features and management.

Authors:  Lela A Lee
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 7.  Congenital heart block: evidence for a pathogenic role of maternal autoantibodies.

Authors:  Aurélie Ambrosi; Marie Wahren-Herlenius
Journal:  Arthritis Res Ther       Date:  2012-04-26       Impact factor: 5.156

8.  Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block.

Authors:  Stina Salomonsson; Sven-Erik Sonesson; Lars Ottosson; Saad Muhallab; Tomas Olsson; Maria Sunnerhagen; Vijay K Kuchroo; Peter Thorén; Eric Herlenius; Marie Wahren-Herlenius
Journal:  J Exp Med       Date:  2005-01-03       Impact factor: 14.307

Review 9.  Autoantibodies and their Judicious Use in Pediatric Rheumatology Practice.

Authors:  Biman Saikia; Amit Rawat; Pandiarajan Vignesh
Journal:  Indian J Pediatr       Date:  2015-12-03       Impact factor: 5.319

10.  Immunomodulation by maternal autoantibodies of the fetal serotoninergic 5-HT4 receptor and its consequences in early BALB/c mouse embryonic development.

Authors:  Rehab Kamel; Simone Garcia; Frank Lezoualc'h; Rodolphe Fischmeister; Sylviane Muller; Johan Hoebek; Pierre Eftekhari
Journal:  BMC Dev Biol       Date:  2007-04-19       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.